Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

The Journal of Skin Cancer, published by HINDAWI LTD, serves as a vital platform for advancing knowledge in the fields of Dermatology and Oncology. Established as an Open Access journal since 2011, it ensures wide dissemination of research findings, making significant contributions to the understanding of skin cancer pathogenesis, diagnosis, and treatment strategies. The journal holds a respectable rank within the academic community, reflected in its Q3 category placement in both Dermatology and Oncology for 2023, as well as its Scopus rankings, which place it in the 49th and 34th percentiles, respectively. Targeting an audience that includes researchers, healthcare professionals, and students, the Journal of Skin Cancer not only aims to present original research but also solicits reviews and case studies, thereby fostering a rich academic dialogue. With its headquarters located in London, England, the journal encourages global engagement and collaboration among scholars committed to improving outcomes in skin cancer.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

Acta Naturae is a peer-reviewed scientific journal published by the Russian Federation Agency for Science & Innovation, focusing on the dynamic fields of Biochemistry, Biotechnology, Molecular Biology, and Molecular Medicine. Launched in 2013, the journal has established a solid reputation in the academic community, with its articles contributing to essential advancements and discussions within these disciplines. By 2023, it has achieved notable rankings—including Q2 status in Biotechnology and Q3 in Biochemistry, Molecular Biology, and Molecular Medicine—indicating its growing influence and relevance in the scientific literature. While currently operating under a non-open access model, Acta Naturae invites researchers, professionals, and students to engage with its comprehensive research reports and reviews that span the breadth of molecular life sciences. With the aim of facilitating scientific dialogue and innovation, this journal serves as a key resource for those seeking to stay at the forefront of molecular research.

CURRENT OPINION IN INFECTIOUS DISEASES, published by Lippincott Williams & Wilkins, is a premier journal that focuses on the latest developments and understanding in the field of infectious diseases. With its ISSN 0951-7375 and E-ISSN 1473-6527, this journal has gained recognition for its pivotal role in advancing knowledge from 1988 to its current publications in 2024. Boasting an impressive Q1 ranking in both Infectious Diseases and the Medical Microbiology category, it holds a reputable position among the top journals in the field. The journal serves as an essential resource for researchers, professionals, and students alike, providing them with timely reviews, analyses, and perspectives that shape contemporary practice and policy. While lacking open access options, it ensures a critical examination of emerging trends and unique insights that foster informed discussions. With its consistently high impact factor, CURRENT OPINION IN INFECTIOUS DISEASES remains a vital platform for thought leaders and innovators navigating the complexities of infectious disease research.

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.